Blood Centers of America member, New York Blood Center, unveils its $50 million investment fund called NYBC Ventures. This newly formed investment fund focusses on blood and cellular therapeutics.
The financing for this new venture is tied to proceeds from solvent detergent plasma processes, patented by NYBC. Since 2021, these funds have been used toward new startups such as Thymmune Therapeutics and STRM.BIO.
Blood Centers of America (BCA) is a member-owned organization comprised of over 50 independent blood centers throughout the North America, representing nearly 40% of the U.S. blood supply. Along with their core business of providing a substantial portion of U.S. blood supply, other BCA member services include patient blood management, transfusion services, immunohematology testing, therapeutic apheresis and tissue and cord blood banking. In addition, BCA members provide a variety of human blood products, cells and tissues to the therapeutic, diagnostic and cell therapy industries.
